Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators. Get payday cash loans today - payday loans online in US.
Popular Articles

HSE Warns Employers To Ensure They Effectively Manage All Traffic Movement On Site
The Health and Safety Executive (HSE) is warning employers to ensure the effective management of the safe movement of pedestrians and vehicles around the workplace, after a man was reversed over by a forklift truck at the new ÷£22.5m shopping complex at Willow Place, Corby.
buy viagra
NYT/CBS News Poll Examines Public Opinion On Sotomayor, Shows Support For Abortion Rights
Three weeks after President Obama named Judge Sonia Sotomayor as his nominee to the Supreme Court, 53% of U.S. adults say they do not know enough about her to determine whether they would support her confirmation, according to a New York Times/CBS News poll released Wednesday, the New York Times reports. The question was one of many in the national telephone poll of 895 adults, which explored a broad range of issues related to Obama"s first five months as president. According to the poll, 48% of participants said that Sotomayor"s opinions on issues like abortion and affirmative action are important information that should be known ahead of her confirmation hearing, which is scheduled to begin July 13. The poll found that 74% of participants believe it is very or somewhat important for the Supreme Court to reflect the nation"s diversity. The Times reports that although Sotomayor"s nomination and the recent murder of Kansas abortion provider George Tiller have "injected a fresh dynamic into the national abortion debate," the new poll shows that there has been little change in public opinion on abortion rights in the past 20 years. Thirty-six percent of participants said that abortion should be generally available, 41% said it should be available but with increased restrictions and 21% said it should be prohibited. Among Democratic voters, 71% said that Roe v. Wade should not be overturned, while Republican voters were "closely divided," the Times reports. The poll was conducted from June 12 to June 16 and has a margin of sampling error of plus or minus three percentage points (Zeleny/Sussman, New York Times, 6/18).
News of the day
Amarillo Biosciences Announces Completion Of Screening Process For Influenza Study In Australia
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that the screening of volunteers for inclusion in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia is now complete. The investigators met their target of screening at least 200 healthy adults for participation in the trial. A total of 215 volunteers were evaluated and 134 of them have been enrolled into the study to date. About 90% of the screened subjects have been found to qualify for the study, so additional enrollments are expected over the next 2 weeks to bring the total number of study participants up to or above the targeted 160 subjects.
Cardiovascular

CircuLite Awarded NIH Grant To Develop The Synergy(R) Micro-Blood Pump For Children And Infants With Life-Threatening Heart Conditions

CircuLite®, Inc. announced that it has been awarded a Fast-Track Phase I-II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to fund the development of a pediatric circulatory assist device based upon CircuLite"s Synergy Pocket Micro-pump. CircuLite, who will collaborate with the University of Maryland School of Medicine on the grant, has received funding from the National Heart, Lung, and Blood Institute at NIH to support the first phase of the grant. The total potential award for Phase I and Phase II could reach up to $3.7 million. Synergy is a micro-blood pump, the size of a AA battery, that can be implanted superficially in a "pacemaker-like" pocket. Synergy is the first and smallest device designed for partial circulatory support (up to 3L/min) and long-term use in adult patients with Class IIIb and early Class IV heart failure. Synergy is currently in a CE Mark clinical trial at multiple centers in Europe. The Synergy device was designed to provide partial circulatory support for the failing adult heart, but its small design makes it a logical candidate for a pediatric application after modification. The aim of Phase I of this grant is to modify the current CircuLite device such that it will be useable in a child and to determine the feasibility of short-term in vivo use. In Phase II, the child system will be finalized and examined in a long-term in vivo study and an infant device will be developed and tested. "This NIH grant is a strong endorsement for Synergy"s unique approach to heart failure treatment, as well as its potential utility to pediatric patients due to its small size and minimally invasive implantation procedure," said Paul Southworth, President and CEO of CircuLite. "While other devices are in development for children and infants, CircuLite believes that Synergy has unique advantages over these other technologies, particularly given its prior successful experience in human clinical trials and its later stage of development as we approach European CE Mark approval later this year. The current study in adults has shown that partial circulatory support provided by Synergy unloads the heart and improves hemodynamics, which can translate into important improvements in functional status and quality of life." "Existing devices do not meet the need for circulatory assistance in pediatric patients, even as hundreds of infants and children with congenital or acquired cardiovascular disease die each year while waiting for a donor heart," said Bartley P. Griffith, M.D., co-investigator on the grant. Dr. Griffith is chief of the Division of Cardiac Surgery and director of Heart and Lung Transplantation in the Department of Surgery at the University of Maryland Medical Center in Baltimore and a professor of surgery at the University of Maryland School of Medicine. "To-date, ventricular assist devices designed for adults have not successfully been redesigned for infants and children, due to difficulties in the miniaturization process of these devices. The goal of this NIH grant is to develop long-term implantable miniature partial circulatory support devices for infants and children, built upon the technology of the already micro-sized Synergy device." About Synergy® The Synergy® Pocket Micro-pump represents a new approach to mechanical circulatory support that is designed to transform chronic heart failure management by providing a less-invasive, elective treatment option for patients before their disease state becomes emergent. Synergy is the first implantable system designed to provide partial circulatory support (PCS) for long-term use in millions of unserved patients that have NYHA Class IIIb/early IV disease. CircuLite"s patented micro-pump provides up to 3L/min of flow, which increases total cardiac output, offloads the heart, allowing it to rest, and potentially enables beneficial recovery of heart function. The size of a AA battery, the device is small enough to be implanted subcutaneously in a "pacemaker-like" pocket through a minimally-invasive procedure. CircuLite®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009